RxDoctor Payments Data

Bushra Khan, MD

Neurology · Houston, TXNPI 1861747289

Payments from drug & device makers

$12,585in general payments, 2019–2025

Across 724 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Biogen$1K
  • Novartis$1K
  • UCB, Inc.$771
  • Supernus Pharmaceuticals, Inc.$733
  • SK Life Science, Inc.$599
  • plus $6K from 45 others

What the payments were for

  • Speaking & faculty fees$180%
  • Food & beverage$12,552100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$12,585 in reported general payments places this provider in the 65th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$36,759
Medicare patients
88
Services billed
243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AptiomEslicarbazepine Acetate67$105,754
BriviactBrivaracetam27$84,513
XcopriCenobamate32$43,049
RexultiBrexpiprazole22$43,034
Rasagiline Mesylate30$8,707
Lamotrigine ErLamotrigine11$7,252
Divalproex Sodium ErDivalproex Sodium45$5,574
Oxcarbazepine37$4,642
Lacosamide24$3,839
Levetiracetam88$3,732
Carbamazepine34$1,959
Carbidopa-LevodopaCarbidopa/Levodopa116$1,921
Topiramate68$1,874
Pregabalin46$1,766
Memantine Hcl51$1,471

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sunovion Pharmaceuticals Inc.Aptiom$507$105,75467 claims
UCB, Inc.Briviact$771$84,51327 claims
SK Life Science, Inc.Xcopri$599$43,04932 claims
Otsuka America Pharmaceutical, Inc.Rexulti$123$43,03422 claims
Upsher-smith Laboratories LLCTopiramate$38$1,87468 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$450$1,18212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,246 neurology providers in Texas.

Other neurology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →